RELMADA THERAPEUTICS, INC. Interest Expense
RELMADA THERAPEUTICS, INC. (RLMD) reported Interest Expense of $1.17 thousand for the 3-month period ending 2015-12-31, per its 10-Q filed 2016-02-05.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2016-02-05
- RELMADA THERAPEUTICS, INC. interest expense for the quarter ending 2015-12-31 was $1.17K, a 6.74% increase year-over-year.
- RELMADA THERAPEUTICS, INC. interest expense for the quarter ending 2015-09-30 was $1.64K, a 49.76% decline year-over-year.
- RELMADA THERAPEUTICS, INC. interest expense for the quarter ending 2015-06-30 was $431.00, a 99.86% decline year-over-year.
- RELMADA THERAPEUTICS, INC. interest expense for the quarter ending 2015-03-31 was $125.00, a 99.90% decline year-over-year.
- RELMADA THERAPEUTICS, INC. interest expense for fiscal 2015 was $4.92K.
- RELMADA THERAPEUTICS, INC. interest expense for fiscal 2013 was $220.31K, a 694.73% increase from fiscal 2012.
- RELMADA THERAPEUTICS, INC. interest expense for fiscal 2012 was $27.72K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month | Interest Expense 115 month | Interest Expense 118 month |
|---|---|---|---|---|---|---|
| 2015-12-31 | $1.17K 10-Q · filed 2016-02-05 | $2.81K 10-Q · filed 2016-02-05 | $3.25K derived: sum of 3 quarters · filed 2016-02-05 | $3.37K derived: sum of 4 quarters · filed 2016-02-05 | ||
| 2015-09-30 | $1.64K 10-Q · filed 2015-11-06 | $2.07K derived: sum of 2 quarters · filed 2015-11-06 | $2.20K derived: sum of 3 quarters · filed 2015-11-06 | $3.30K derived: sum of 4 quarters · filed 2016-02-05 | ||
| 2015-06-30 | $431.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-11 | $556.00 derived: sum of 2 quarters · filed 2015-09-11 | $1.65K derived: sum of 3 quarters · filed 2016-02-05 | $4.92K 10-K · filed 2015-09-11 | ||
| 2015-03-31 | $125.00 10-Q · filed 2015-05-15 | $1.22K derived: sum of 2 quarters · filed 2016-02-05 | $4.49K 10-Q · filed 2015-05-15 | $316.30K derived: sum of 4 quarters · filed 2016-02-05 | ||
| 2014-12-31 | $1.10K 10-Q · filed 2016-02-05 | $4.37K 10-Q · filed 2016-02-05 | $316.18K derived: sum of 3 quarters · filed 2016-02-05 | $439.98K derived: sum of 4 quarters · filed 2016-02-05 | ||
| 2014-09-30 | $3.27K 10-Q · filed 2015-11-06 | $315.08K derived: sum of 2 quarters · filed 2015-11-06 | $438.88K derived: sum of 3 quarters · filed 2015-11-06 | $550.51K derived: sum of 4 quarters · filed 2015-11-06 | ||
| 2014-06-30 | $311.81K derived: 10-K 6 month − 10-Q 3 month · filed 2015-09-11 | $435.61K 10-K · filed 2015-09-11 | $547.24K derived: sum of 3 quarters · filed 2015-09-11 | $614.25K derived: sum of 4 quarters · filed 2015-09-11 | ||
| 2014-03-31 | $123.80K 10-Q · filed 2015-05-15 | $235.43K derived: sum of 2 quarters · filed 2015-05-15 | $302.44K 10-Q · filed 2015-05-15 | $1.21M 8-K · filed 2014-05-27 | ||
| 2013-12-31 | $111.63K 10-Q · filed 2015-02-13 | $178.64K 10-Q · filed 2015-02-13 | $220.31K 10-K · filed 2015-09-11 | $1.09M 8-K · filed 2014-05-27 | ||
| 2013-09-30 | $67.01K 10-Q · filed 2014-11-07 | |||||
| 2013-03-31 | $29.42K 8-K · filed 2014-05-27 | |||||
| 2012-12-31 | $27.72K 10-KT · filed 2014-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |